Risk stratification tools and shared decisionmaking frameworks help identify patients most likely to benefit
BPC-157 is not approved for human use in the UK and is sold for research purposes only
It may have a lower risk of gastrointestinal side effects compared to the injectable version, though some users still report nausea and stomach discomfort
& Waki, T
Besides, 7-chloro-4-(phenylselanyl) quinoline (4-PSQ) with antinociceptive, antioxidant, and neuroprotective effects has also been studied
These products have not been tested in large, randomized clinical trials, may vary in strength or purity, and may not even contain the same active ingredient as FDA-approved semaglutide, said Fatima Cody Stanford, MD, MPH, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School, both in Boston